Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice

Memorias do Instituto Oswaldo Cruz; Borborema, Samanta Etel Treiger; Osso Junior, Joao Alberto; Andrade Junior, Heitor Franco de; Nascimento, Nanci do.
Mem. Inst. Oswaldo Cruz ; 108(5): 623-630, ago. 2013. tab, graf
Artigo em Inglês | LILACS | ID: lil-680768

Documentos relacionados

  1. Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.
  2. Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate.
  3. Anti-<i>Leishmania</i> compounds can be screened using <i>Leishmania</i> spp. expressing red fluorescence (<i>tdTomato</i>).
  4. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
  5. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression.
  6. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
  7. Inhibition of <i>Leishmania infantum</i> Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site.
  8. Effect of the aggregated protein dye YAT2150 on <i>Leishmania</i> parasite viability.
  9. An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis.
  10. Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance.